Daniel Touchette
Full Professor, College of Pharmacy - Pharmacy Systems Outcomes and Policy
Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago
Director of Graduate Studies, Masters of Science in Comparative Effectiveness Research
Contact
Address:
833 S Wood St. MC 871, Chicago, Illinois
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
My primary research interests are in the areas of pharmacoeconomics and comparative effectiveness research. I am particularly interested in evaluating innovative methods of delivering health care to complex patients with multiple chronic conditions to improve clinical outcomes and quality of life in an efficient manner. This includes, but is not limited to, the evaluation of clinical pharmacist and multidisciplinary activities such as medication therapy management and medical home models; development of programs to improve adherence to medications; and evaluation of pharmaceutical agents for efficiency and optimizing their use. Scientific methods employed in my research include cost-of-illness and cost-effectiveness analysis, pharmacoepidemiologic methods, and prospective comparative effectiveness trials.
Teaching and Supervision Heading link
Comp Effectiveness Res Proj (PSOP 592), 8/22/2022 – 12/2/2022
Ph.D. Thesis Research (PSOP 599), 8/22/2022 – 12/2/2022
Independent Study (PSOP 596), 8/22/2022 – 12/2/2022
Res in Pharm Syst Outcomes Pol (PSOP 380), 8/22/2022 – 12/2/2022
CER Ethics and Privacy (PSOP 400), 8/22/2022 – 12/2/2022
Social and Behavioral Pharmacy (PHAR 462), 8/22/2022 – 10/28/2022
Social and Behavioral Pharmacy (PHAR 462), 8/22/2022 – 10/28/2022
Ph.D. Thesis Research (PSOP 599), 5/16/2022 – 7/21/2022
Comp Effectiveness Res Proj (PSOP 592), 5/16/2022 – 7/21/2022
Selected Grants
2022 - 2023 Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical and Economic Review., 1/1/2022 - 12/31/2023, Obligated Amount: $340000; Anticipated Amount: $340000
AbbVie Fellowship 2021-2023 - Dan Touchette and Mrinmayee Joshi, AbbVie, Inc.., 7/1/2021 - 6/30/2023, Obligated Amount: $201352; Anticipated Amount: $201352
Cost Effectiveness Analysis of Allogeneic Islet Cell Transplantation for Brittle Type 1 Diabetes, The Chicago Diabetes Project., 8/15/2020 - 7/31/2022, Obligated Amount: $40666; Anticipated Amount: $40666
2020 - 2021 Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical and Economic Review., 1/1/2020 - 12/31/2021, Obligated Amount: $425000; Anticipated Amount: $425000
An Etiology for Medication Ordering Errors in CPOE Systems, Washington University in St. Louis., 8/1/2018 - 7/31/2020, Obligated Amount: $56788; Anticipated Amount: $56788
Institute for Clinical and Economic Review consulting agreement for developing pharmacoeconomic models, Institute for Clinical and Economic Review (UIC contract #2017-001).., 6/30/2018 - 6/30/2019, Obligated Amount: $62500; No Anticipated Amount Set
An Etiology for Medication Ordering Errors in CPOE Systems, US Department of Health & Human Services (Agency for Healthcare Research & Quality)., 8/1/2017 - 7/31/2019, Obligated Amount: $142885; Anticipated Amount: $299999
Cost-Effectiveness Analysis of Injectable Extended Release Naltrexone versus Buprenorphine/Naloxone for Treatment of Opioid Dependence in the United States: A Primary Care Perspective, Amer Coll of Clinical Pharmacy (ACCP)., 7/1/2017 - 6/30/2018, Obligated Amount: $500; Anticipated Amount: $500
Institute for Clinical and Economic Review consulting agreement for developing pharmacoeconomic models, Institute for Clinical and Economic Review (UIC contract #2017-001).., 3/31/2017 - 6/30/2018, Obligated Amount: $62500; No Anticipated Amount Set
Selected Publications
EVANS, KRISTIN A, POLLACK, MICHAEL, TKACZ, JOSEPH, TOUCHETTE, DANIEL R, PORTILLO, EDWARD C, STRANGE, CHARLIE, STARESINIC, ANTHONY, PATEL, SUSHMA M, FEIGLER, NORBERT. (2022). PROMPTLY INITIATING TRIPLE THERAPY FOLLOWING SECOND MODERATE EXACERBATION AMONG PATIENTS WITH COPD IN THE UNITED STATES: ANALYSIS OF THE PRIMUS STUDY. CHEST Journal, 162, (4), a1901-a1902. doi:10.1016/j.chest.2022.08.1582.
Joshi, M, Pham, CM, Deng, H, Norton, RM, Mathew, S, Tilton, JJ, Touchette, . (2022). EE269 Long-Term Cost-Effectiveness of a Pharmacist-Led Medication Therapy Management Clinic (MTMC) for Type 2 Diabetes Management. Value in Health, 25, (7), s386. doi:10.1016/j.jval.2022.04.516.
Tkacz, J, Evans, KA, Touchette, DR, Portillo, E, Strange, C, Staresinic, A, Feigler, N, Patel, S, Pollack, M. (2022). PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation. International Journal of COPD, 17, 329-342. doi:10.2147/COPD.S347735.
Tice, JA, Touchette, DR, Lien, PW, Agboola, F, Nikitin, D, Pearson, SD. (2022). The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. Journal of Managed Care and Specialty Pharmacy, 28, (1), 119-124. doi:10.18553/JMCP.2022.28.1.119.
Touchette, DR, Rodriguez, R. (2021). Part II: Survival analysis and common applications. JACCP Journal of the American College of Clinical Pharmacy, 4, (12), 1624-1630. doi:10.1002/jac5.1562.
Talon, B, Calip, GS, Lee, TA, Sharp, LK, Patel, P, Touchette, DR. (2021). Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients with Chronic Myelogenous Leukemia. JCO Oncology Practice, 17, (11), E1811-E1820. doi:10.1200/OP.20.00967.
Tkacz, Joseph, Evans, Kristin, Touchette, Daniel, Portillo, Ed, Strange, Charlie, Staresinic, Anthony, Feigler, Norbert, Patel, Sushma, Pollack, Michael. (2021). PROMPT INITIATION OF MAINTENANCE THERAPY IN THE UNITED STATES (PRIMUS): AN ANALYSIS OF TRIPLE THERAPY FOLLOWING A DISEASE EXACERBATION AMONG PATIENTS WITH COPD. CHEST Journal, 160, (4), a1809-a1810. doi:10.1016/j.chest.2021.07.1635.
Joshi, M, Atlas, SJ, Rind, DM, Beinfeld, M, McKenna, A, Patel, S, Chapman, RH, Pearson, S, Touchette, D. (2021). PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC). Value in Health, 24, s33. doi:10.1016/j.jval.2021.04.166.
Beinfeld, M, Atlas, SJ, Touchette, D, McKenna, A, Rind, D, Pearson, SD. (2021). The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. Journal of Managed Care and Specialty Pharmacy, 27, (6), 797-804. doi:10.18553/JMCP.2021.27.6.797.
Professional Leadership
Associate Editor, BMC Health Services Research, 4/1/2018 - 8/31/2021
Education
Degrees:
Masters in Arts, Wayne State University, United States, 2000
Fellowship in Pharmacoeconomics and Outcomes Research, Wayne State University, United States, 1999
Doctor of Pharmacy, Wayne State University, United States, 1997
Bachelors of Science, University of Manitoba, Canada, 1991
Licensures and Certifications
Geriatric Pharmacy Update Certificate Course, University of Manitoba, Date Not Set - 1992
Current Issues in Chemical Dependency Certificate Course, University of Manitoba, Date Not Set - 1993
Graduate Summer Session in Epidemiology Certificate Program, University of Michigan–Ann Arbor, Date Not Set - 1998
Professional Licensure (Registered Pharmacist), State of Michigan, Date Not Set - Present
Selected Presentations
Touchette, Daniel. (2022 February 03). Is there a cure for health care? (updated). UIC Pharmacy Systems & Outcomes Seminar. Chicago.
Touchette, DANIEL. (2022 February 01). Justification of MTM Services at UIC: A Discussion of Collaborative Research.. American College of Clinical Pharmacy Health Outcomes PRN Research Webinar. Virtual.
Touchette, DANIEL. (2021 November 06). Is There a Cure for Healthcare?. St. Joseph/Candler Health System 2021 Advance. Sea Island, GA.